GlassScriptPhysician profile
Mary Ransom
NPI 1487697389
$12,399.24
in general payments reported to CMS, 2019-2025
65 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,517 · 2020: $1,635 · 2021: $2,871 · 2022: $2,495 · 2023: $844 · 2024: $921 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,882.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,881.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,204.88 | 2019-2023 | |
| Ucb, INC. | $1,089.95 | 2019-2024 | Briviact, Nayzilam |
| Biogen, INC. | $885.07 | 2019-2023 | Vumerity |
| Sk Life Science, INC. | $720.22 | 2020-2024 | Xcopri |
| Genzyme Corporation | $696.89 | 2019-2022 | |
| Abbvie INC. | $564.78 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $560.00 | 2019-2024 | Ultomiris |
| Greenwich Biosciences, INC. | $513.53 | 2019-2021 | |
| Kyowa Kirin, INC. | $436.65 | 2020-2023 | Nourianz |
| Emd Serono, INC. | $400.92 | 2019-2025 | Mavenclad |
| Sunovion Pharmaceuticals INC. | $400.74 | 2019-2022 | |
| Eisai INC. | $313.72 | 2019-2022 | |
| Genentech USA, INC. | $306.63 | 2019-2021 | |
| Amgen INC. | $304.85 | 2019-2023 | Aimovig |
| Teva Pharmaceuticals USA, INC. | $265.56 | 2019-2022 |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Ransom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.